Melih Ustaoglu, MD
Retina Specialist · Terre Haute, INNPI 1609405257
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (52.1%), travel and lodging and grants — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by Bausch & Lomb Americas Inc. at 36.4% of the total. Reporting peaked in 2022 at $1,790 and has fallen 95.4% since, to $82 in 2025.
Across 39 payments — averaging $90.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$1K
- Regeneron$832
- Regeneron Healthcare Solutions, Inc.$268
- Alcon$250
- Apellis Pharmaceuticals, Inc.$204
- Genentech USA, Inc.$204
- plus $496 from 5 others
What the payments were for
- Grants$70020%
- Travel & lodging$98128%
- Food & beverage$1,84552%
- Education$170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 11 | $1,290 |
| Regeneron | 2 | $832 |
| Regeneron Healthcare Solutions, Inc. | 4 | $268 |
| Alcon | 2 | $250 |
| Apellis Pharmaceuticals, Inc. | 5 | $204 |
| Genentech USA, Inc. | 5 | $204 |
| Astellas Pharma US Inc | 6 | $127 |
| AbbVie | 1 | $125 |
| Ocular Therapeutix, Inc. | 1 | $111 |
| Amgen | 1 | $109 |
| Harrow Eye, LLC | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- STELLARIS$1,031
- OPHTHALMIC INSTRUMENTS$1,031
- EYLEA$360
- Clareon$127
- DURYSTA$125
- VABYSMO$125
- Hydrus Microstent$123
- Syfovre$122
- DEXTENZA$111
- TEPEZZA$109
How this compares
$3,542 in reported general payments places this provider in the 70th percentile of 21 retina specialist providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 88 | $3,844 |
| Ketorolac Tromethamine | 62 | $947 |
| Brimonidine Tartrate | 17 | $881 |
| MoxifloxacinMoxifloxacin Hcl | 25 | $773 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 35 | $690 |
| Timolol Maleate | 27 | $256 |
| Latanoprost | 12 | $95 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Terre Haute
- Alexander IzadTerre Haute$1K
- Ankur ShahCarmel$569K
- Raj MaturiCarmel$100K
- Ramana MoorthyCarmel$61K
- Milan ShahCarmel$35K
- Rodney BucherCarmel$30K
- Frank HrisomalosIndianapolis$4K
- Howard LazarusNew Albany$3K
- Julia HudsonCarmel$3K
- Steven VirataLafayette$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.